TCRαβ/CD19 cell–depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis
Blood · 2024
DOI: 10.1182/blood.2023021336 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2024. Verfasst von Pietro Merli und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, Istituto di Ricovero e Cura a Carattere Scientifico Bambino Gesù Children's Hospi…. Hauptthemen laut MEDLINE: Graft vs Host Disease, Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
TCRαβ/CD19 cell depletion is a promising graft manipulation technique frequently used in the context of human leukocyte antigen (HLA)–haploidentical hematopoietic stem cell transplantation (HSCT). We previously reported the results of a phase I-II clinical trial (NCT01810120) to assess the safety and the efficacy of this type of exvivo T-cell depletion in 80 children with acute leukemia, showing promising survival outcomes. We now report an updated analysis on a cohort of 213 children with a longer follow-up (median, 47.6 months for surviving patients). With a 5-year cumulative incidence of nonrelapse mortality of 5.2% (95% confidence interval [CI], 2.8%-8.8%) and a cumulative incidence of relapse of 22.7% (95% CI, 16.9%-29.2%), projected 10-year overall and disease-free survival (DFS) were 75.4% (95% CI, 68.6%-80.9%) and 71.6% (95% CI, 64.4%-77.6%), respectively. Cumulative incidence of both grade II-IV acute and chronic graft-versus-host disease were low (14.7% and 8.1%, respectively). In a multivariable analysis for DFS including type of disease, use of total body irradiation in the conditioning regimen (hazard ratio [HR], 0.5; 95% CI, 0.26-0.98; P = .04), disease status at HSCT (complete remission [CR] ≥3 vs CR 1/2; HR, 2.23; 95% CI, 1.20-4.16; P = .01), and high levels of pre-HSCT minimal residual disease (HR, 2.09; 95% CI, 1.01-4.33; P = .04) were independently associated with outcome. In summary, besides confirming the good outcome results already reported (which are almost superimposable on those of transplant from HLA-matched donors), this clinical update allows the identification of patients at higher risk of treatment failure for whom personalized approaches, aimed at reducing the risk of relapse, are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, Istituto di Ricovero e Cura a Carattere Scientifico Bambino Gesù Children's Hospital, Rome, Italy.
- Transfusion Unit, Department of Laboratories, Istituto di Ricovero e Cura a Carattere Scientifico Bambino Gesù Children's Hospital, Rome, Italy.
- Pediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, University of Padua, Padua, Italy.
- Laboratory of Clinical and Experimental Immunology, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
- Laboratory of Pathology and Experimental Immunology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
- Department of Health Science and Public Health, Catholic University of the Sacred Heart, Rome, Italy.
ORCID-Profile: Pietro Merli, Federica Galaverna, Valentina Bertaina, Marco Becilli, Francesco Quagliarella, Raffaella Sborgia, Maria Luigia Catanoso, Luisa Strocchio, Raffaella Meazza, Daniela Pende, Marco Andreani, Franco Locatelli
Zitieren
APA
Merli, P., Algeri, M., Galaverna, F., Bertaina, V., Lucarelli, B., Boccieri, E., Becilli, M., Quagliarella, F., Rosignoli, C., Biagini, S., Girolami, E., Meschini, A., Del Principe, G., Sborgia, R., Catanoso, M. L., Carta, R., Strocchio, L., Pinto, R. M., Buldini, B., …, & Locatelli, F. (2024). TCRαβ/CD19 cell–depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis. Blood. https://doi.org/10.1182/blood.2023021336
Vancouver
Merli P, Algeri M, Galaverna F, Bertaina V, Lucarelli B, Boccieri E, et al. TCRαβ/CD19 cell–depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis. Blood. 2024. doi:10.1182/blood.2023021336
BibTeX
@article{Merli2024,
author = {Merli, Pietro and Algeri, Mattia and Galaverna, Federica and Bertaina, Valentina and Lucarelli, Barbarella and Boccieri, Emilia and Becilli, Marco and Quagliarella, Francesco and Rosignoli, Chiara and Biagini, Simone and Girolami, Elia and Meschini, Antonella and Del Principe, Giovanna and Sborgia, Raffaella and Catanoso, Maria Luigia and Carta, Roberto and Strocchio, Luisa and Pinto, Rita Maria and Buldini, Barbara and Falco, Michela and Meazza, Raffaella and Pende, Daniela and Andreani, Marco and Li Pira, Giuseppina and Pagliara, Daria and Locatelli, Franco},
title = {TCRαβ/CD19 cell–depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis},
journal = {Blood},
year = {2024},
doi = {10.1182/blood.2023021336}
}
EUVIMED